Frara Stefano, Losa Marco, Doga Mauro, Formenti Anna Maria, Mortini Pietro, Mazziotti Gherardo, Giustina Andrea
Institute of Endocrinology, Università Vita-Salute San Raffaele, Milan, Italy.
Institute of Neurosurgery, Università Vita-Salute San Raffaele, Milan, Italy.
J Endocr Soc. 2018 Jul 27;2(9):1089-1099. doi: 10.1210/js.2018-00091. eCollection 2018 Sep 1.
Bone loss and high risk of fractures have been reported in patients with primary hyperthyroidism, whereas data on skeletal health in TSH-secreting adenoma (TSH-oma) are scant, and the risk of fractures in this specific clinical context has not been investigated so far. In this cross-sectional study, we aimed at evaluating for the first time, to our knowledge, the prevalence and determinants of radiological vertebral fractures (VFs) in patients with TSH-oma.
Twenty-two patients (10 males, 12 females; median age 47 years) with TSH-oma and 44 patients (20 males, 24 females; median age 49 years) with nonfunctioning pituitary adenoma (NFPA) were retrospectively evaluated for thoracic VFs using a morphometric approach on lateral chest X-ray routinely performed in the presurgical diagnostic workup.
The prevalence of VFs was significantly higher in TSH-oma vs NFPA (59.1% vs 22.7%; = 0.003), the difference being still significant (odds ratio, 10.5; = 0.005) after correction for the size of pituitary adenomas and biochemical parameters. In TSH-oma, the prevalence of VFs was significantly associated with older age ( = 0.007) and higher serum free T4 values ( = 0.02). In 20 patients, data on presurgical medical therapies of TSH-oma were available. All patients not treated with somatostatin receptor ligands were fractured compared with 25% of those who were treated with these drugs ( = 0.001). No significant ( = 0.25) association between VFs and treatment with methimazole was found.
This study provides the first evidence, to our knowledge, that patients with TSH-oma may develop VFs in close relationship with severity of hyperthyroidism.
原发性甲状腺功能亢进症患者中已报道存在骨质流失和骨折高风险,而关于促甲状腺激素分泌腺瘤(TSH瘤)患者骨骼健康的数据较少,且目前尚未对这一特定临床背景下的骨折风险进行研究。在这项横断面研究中,据我们所知,我们旨在首次评估TSH瘤患者放射性椎体骨折(VF)的患病率及其决定因素。
对22例TSH瘤患者(10例男性,12例女性;中位年龄47岁)和44例无功能垂体腺瘤(NFPA)患者(20例男性,24例女性;中位年龄49岁)进行回顾性评估,在术前诊断检查中常规进行的胸部侧位X线片上采用形态计量学方法评估胸椎VF。
TSH瘤患者VF的患病率显著高于NFPA患者(59.1%对22.7%;P = 0.003),在校正垂体腺瘤大小和生化参数后,差异仍然显著(优势比,10.5;P = 0.005)。在TSH瘤患者中,VF的患病率与年龄较大(P = 0.007)和血清游离T4值较高(P = 0.02)显著相关。在20例患者中,可获得TSH瘤术前药物治疗的数据。未接受生长抑素受体配体治疗的所有患者均发生骨折,而接受这些药物治疗的患者中有25%发生骨折(P = 0.001)。未发现VF与甲巯咪唑治疗之间存在显著关联(P = 0.25)。
据我们所知,本研究首次提供证据表明,TSH瘤患者可能发生与甲状腺功能亢进严重程度密切相关的VF。